Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
The UNICANCER-NeoPAL study of letrozole and palbociclib in luminal cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 2153

Dr Paul Cottu - Institut Curie, Paris, France

Dr Cottu speaks with ecancer at the ESMO 2017 Congress about the phase II UNICANCER-NeoPAL study combining letrozole and palbociclib as neoadjuvant treatment of luminal breast cancer. 

Neoadjuvant LP led to a slightly lower pCR/RCB 0-I rate than chemo, however clinical response and breast conserving surgery rates were similar in both arms and LP had a much better safety profile.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence